Skip to content

ISSN: 1792-7110

HAEMA

The Journal of the Hellenic Society of HAEMATOLOGY

HOME
ABOUT
- JOURNAL INFORMATION
- EDITORIAL BOARD
CURRENT ISSUE
AUTHORS
ARCHIVE
SUBMIT YOUR MANUSCRIPT
CONTACT US

Category: HAEMA 2012 (4)

23rd Panhellenic Hematological Congress

Posted on June 26, 2018June 26, 2018 by admin

Haema 2012; 3(4)

CONGRESS PROCEEDINGS

Full PDF (in Greek) |

Posted in HAEMA 2012 (4)

SEARCH

CURRENT ISSUE

Post of 64th American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022 New Orleans, USA

Post ASH 2022: Acute Myeloid Leukemia

Post ASH 2022: Paroxysmal Nocturnal Hemoglobinuria and thrombotic microangiopathies

Post ASH 2022: Key studies in chronic lymphocytic leukemia (CLL)

Post ASH 2022: Mantle cell and low grade B-Cell Lymphomas

Post ASH 2022: Hodgkin lymphoma, what’ new?

Post ASH 2022: High-grade B-cell Lymphomas, what’s new?

Post ASH 2022: Hemoglobinopathies

About Us

HAEMA is the official journal of the Hellenic Society of Hematology. HAEMA was founded in March 1998, since when it has been published regularly and has undergone several modifications,in both the language (Greek-English) and the content of the journal.
The new edition of HAEMA is an English language, independent, open-access, peer reviewed journal, published quarterly.
FIND ARTICLE BY KEYWORD

Acalabrutinib (1) Acute myeloid leukemia (1) Acute myeloid leukemia (AML) (2) AML (1) Azacitidine (2) bcl-2 inhibitors (1) bispecific antibodies (1) brentuximab vedotin (1) bruton kinase inhibitors (1) CAR-T cells (2) CAR T-cell therapies (1) chronic lymphocytic leukemia (1) Clinical trials (1) cold-agglutinin disease (1) complement (1) ctDNA (1) DLBCL (2) favezelimab (1) Follicular lymphoma (1) frontline treatment (1) Hemoglobinopathy (1) high risk disease (2) Hodgkin lymphoma (2) ibrutinib (1) IDH1/IDH2 mutations (1) intensive chemotherapy (2) International Consensus Classification (ICC) 2022 (2) magrolimab (2) Mechanism of action (1) nivolumab (1) novel agents (1) Paroxysmal nocturnal hemoglobinuria (1) pembrolizumab (1) pirtobrutinib (1) Prognosis (2) prognostic factors (1) sickle cell disease (1) thalassemia (1) thrombotic microangiopathies (1) Thrombotic microangiopathy (1) Thrombotic thrombocytopenic purpura (2) Treatment (2) Venetoclax (4) WHO 2022 Classification (2) zanubrutinib (1)

Theme by Out the Box